

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 35D0991209	(X3) Date Survey Completed 06/03/2025
Name of Provider or Supplier Medscan Laboratory, Inc	Street Address, City, State 1502 13th Ave W Suite 201, Williston, ND	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D5217	<p>EVALUATION OF PROFICIENCY TESTING PERFORMANCE CFR(s): 493.1236(c)(1)</p> <p>At least twice annually, the laboratory must verify the accuracy of any test or procedure it performs that is not included in subpart I of this part.</p> <p>This STANDARD is not met as evidenced by: Based on record review, staff interview, and policy review, the laboratory failed to twice annually verify the accuracy of 32 of 136 non-regulated analytes (Hydroxyethylflurazepam, 3-hydroxy-LSD, 25I-NBOMe, Fluorophenmetrazine, 3-Methylhistidine, AB-Pinaca, Atomoxetine, Baclofen, Buspirone, Chlorpromazine, Desmethylvenlafaxine, Dibutylone, Fluvoxamine, Hydroxyrisperidone, Lacosamide, MDPV (Methylenedioxypropylvalerone), Methocarbamol, Methylone, N-Ethylpentylone, Naltrexone, Norcocaine, Normetanephrine, Orphenadrine, Pentazocine, Ramelteon, Risperidone, Ritalinic Acid, Rizatriptan, Sufentanil, Sumatriptan, Tianeptine, Zolpidem COOH) in 2024. The laboratory performed approximately 60,000 to 90,000 of each of these analytes for patient testing in 2024. Findings include: 1. Reviewed at 9:00 a.m. on 06/03/25, the laboratory's test menu listed Hydroxyethylflurazepam, 3-hydroxy-LSD, 25I-NBOMe, Fluorophenmetrazine, 3-Methylhistidine, AB-Pinaca, Atomoxetine, Baclofen, Buspirone, Chlorpromazine, Desmethylvenlafaxine, Dibutylone, Fluvoxamine, Hydroxyrisperidone, Lacosamide, MDPV (Methylenedioxypropylvalerone), Methocarbamol, Methylone, N-Ethylpentylone, Naltrexone, Norcocaine, Normetanephrine, Orphenadrine, Pentazocine, Ramelteon, Risperidone, Ritalinic Acid, Rizatriptan, Sufentanil, Sumatriptan, Tianeptine, and Zolpidem COOH tests available for patient testing. 2. Reviewed at 9:30 a.m. on 06/03/25, the 2024 proficiency testing records indicated the laboratory did not participate in proficiency testing for Hydroxyethylflurazepam, 3-hydroxy-LSD, 25I-NBOMe, Fluorophenmetrazine, 3-Methylhistidine, AB-Pinaca, Atomoxetine, Baclofen, Buspirone, Chlorpromazine, Desmethylvenlafaxine, Dibutylone, Fluvoxamine, Hydroxyrisperidone, Lacosamide, MDPV</p>

(Methylenedioxypropylamphetamine), Methocarbamol, Methylone, N-Ethylpentylone, Naltrexone, Norcocaine, Normetanephrine, Orphenadrine, Pentazocine, Ramelteon, Risperidone, Ritalinic Acid, Rizatriptan, Sufentanil, Sumatriptan, Tianeptine, and Zolpidem COOH analytes. 3. Upon request, the laboratory failed to provide evidence of a twice annual accuracy verification in 2024 for the above 32 toxicology analytes. 4. During interview at 1:36 p.m. on 06/03/25, an administrative staff member (#1) confirmed the laboratory performed patient testing on the above 32 analytes in 2024 and did not verify the accuracy of these tests in 2024. 5. Upon request, the laboratory failed to provide a policy related to twice annual accuracy verification of non-regulated analytes.